Tryp Therapeutics: Unlocking the potential of psychedelics for chronic pain

Published on 22 October 2021

Tryp Therapeutics is a pharmaceutical company that is leading the next wave of psychedelic drug development beyond mental health with its focus on chronic pain and other indications. In this video, Greg McKee, chairman and CEO, discusses Tryp’s clinical development programmes for fibromyalgia, phantom limb pain and other areas as well as the company’s rationale for using psilocybin for chronic pain.

Share this with friends and colleagues